Heron Therapeutics, Inc. cash flow to debt ratio of -19.62% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Heron Therapeutics, Inc.'s free cash flow has decreased 15.16% from $-24.23M last year to $-27.91M, signaling decreasing performance

Heron Therapeutics, Inc.'s debt to equity ratio is 21.48, which means that the company's assets are unhealthy financed, signaling financial risk.

Heron Therapeutics, Inc.'s debt has increased relative to shareholder equity from -5.28 last year to 21.48 today, signaling weakened financials

Heron Therapeutics, Inc. has negative EBITDA, making leverage ratio unreliable

Heron Therapeutics, Inc.'s interest coverage ratio is -2.79, which means that the company struggles to meet interest obligations, signaling financial risk.

Heron Therapeutics, Inc.'s profit margin has decreased (139.30%) in the last year from -9.41% to -22.52%, signaling decreasing performance

Heron Therapeutics, Inc.'s short-term assets of $238.07M exceed its short-term liabilities of $96.10M

Heron Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Heron Therapeutics, Inc.'s return on equity of -300.90%, is lower than 15.00%, indicating bad performance

Heron Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Heron Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Heron Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Heron Therapeutics, Inc. has negative free cash flow, indicating cash burn

Heron Therapeutics, Inc.'s yearly earnings has decreased 48.71% since last year from $-13.58M to $-20.20M, signaling decreasing performance

Heron Therapeutics, Inc.'s yearly revenue has increased 7.36% since last year from $144.28M to $154.90M, signaling increasing performance

ROIC -6.78% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Heron Therapeutics, Inc.'s 3-year revenue CAGR of 12.89% is positive, indicating growing revenue over the past 3 years

Heron Therapeutics, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Heron Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Heron Therapeutics, Inc. has insufficient data to evaluate this check.

Heron Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Heron Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Heron Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Heron Therapeutics, Inc. has insufficient data to evaluate this check.

Heron Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Heron Therapeutics, Inc. has a price-to-book ratio of 9.23x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Heron Therapeutics, Inc. has a price-to-sales ratio of 0.42x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue